140 related articles for article (PubMed ID: 33092743)
21. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
Thomas LE; Bonow RO; Pencina MJ
JAMA Cardiol; 2020 Sep; 5(9):988-990. PubMed ID: 32936260
[No Abstract] [Full Text] [Related]
22. Response to "COVID-19 and ACEI/ARB: Not Associated?".
Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
[No Abstract] [Full Text] [Related]
23. COVID-19 and ACEI/ARB: Not Associated?
Hajra A; Bandyopadhyay D
Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
[No Abstract] [Full Text] [Related]
24. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Cappuccio FP; Siani A
Nutr Metab Cardiovasc Dis; 2020 Jul; 30(8):1227-1235. PubMed ID: 32595085
[TBL] [Abstract][Full Text] [Related]
25. Comment on "ACE inhibitors and COVID-19: We don't know yet".
Ilcol TB; Cure E; Cumhur Cure M
J Card Surg; 2020 Jun; 35(6):1387. PubMed ID: 32531125
[No Abstract] [Full Text] [Related]
26. Observational data during the COVID-19 pandemic: opportunity with uncertainty.
Straw S; Witte KK
Heart; 2020 Oct; 106(19):1461-1462. PubMed ID: 32759292
[No Abstract] [Full Text] [Related]
27. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
28. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
Trifirò G; Crisafulli S; Andò G; Racagni G; Drago F;
Drug Saf; 2020 Jun; 43(6):507-509. PubMed ID: 32303915
[No Abstract] [Full Text] [Related]
29. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
30. Cardiovascular disease and the impact of COVID-19.
Yoganathan A; Sajjad MS; Harky A
J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
[No Abstract] [Full Text] [Related]
31. Letter to the editors in response to: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic (Cure et al.).
Ekiz T; Kara M; Özçakar L
Diabetes Metab Syndr; 2020; 14(4):525-526. PubMed ID: 32402930
[No Abstract] [Full Text] [Related]
32. Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
Otto CM
Heart; 2020 Oct; 106(19):1451-1453. PubMed ID: 32928982
[No Abstract] [Full Text] [Related]
33. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
Henry RA
CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254
[No Abstract] [Full Text] [Related]
34. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.
Speth RC
Drug Dev Res; 2020 Sep; 81(6):643-646. PubMed ID: 32304146
[No Abstract] [Full Text] [Related]
35. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
36. In reply-Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G
Mayo Clin Proc; 2020 Jul; 95(7):1553-1556. PubMed ID: 32622458
[No Abstract] [Full Text] [Related]
37. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial.
Thomas LE; Li F; Pencina MJ
JAMA; 2020 Jun; 323(23):2417-2418. PubMed ID: 32369102
[No Abstract] [Full Text] [Related]
38. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy.
Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L
Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624
[No Abstract] [Full Text] [Related]
39. ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?
Murthy VL; Koupenova M; Shah RV
Circ Res; 2020 Jun; 126(12):1682-1684. PubMed ID: 32302248
[No Abstract] [Full Text] [Related]
40. Facts and reflections on COVID-19 and anti-hypertensives drugs.
Marin GH
Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
